Specialized multidisciplinary care improves ALS survival in Belgium: a population-based retrospective study

References

• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181–93.
   PubMed Web of Science ®Google Scholar
• Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465–79.
   PubMed Web of Science ®Google Scholar
• Rich KA, Roggenbuck J, Kolb SJ. Searching far and genome-wide: the relevance of association studies in amyotrophic lateral sclerosis. Front Neurosci. 2020;14:603023.
   PubMed Web of Science ®Google Scholar
• Wales S, Kiernan C, DSc Cheah AM, Burrell M, Biostat BC, MBBS Zoing J, Kiernan B, MC, MC, et al. Seminar Amyotrophic lateral sclerosis. Lancet 2011;377:942–55. [Internet]. Available from: www.thelancet.com
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996; 347:1425–31.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994; 330:585–91.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH,. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.
   Google Scholar
• Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022; 387:1099–110.
   PubMed Web of Science ®Google Scholar
• Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661–70. Vol. Nature Publishing Group;
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012; 19:360–75.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000 [Internet]. J Neurol Neurosurg Psychiatry. 2003;74:1258–61. Available from: www.jnnp.com
   PubMed Web of Science ®Google Scholar
• Paipa AJ, Povedano M, Barcelo A, Domínguez R, Saez M, Turon J, et al. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in spain: Association with noninvasive mechanical ventilation. J Multidiscip Healthc. 2019;12:465–70.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival: Results from a population-based study in Southern Italy. J Neurol. 2007; 254:1107–12.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21. [Internet]. Vol. Available from: www.elsevier.com/locate/jns
   PubMed Web of Science ®Google Scholar
• Bakker LA, Schröder CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017; 264:1413–20.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018; 17:423–33.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10:310–23. Vol.
   PubMed Web of Science ®Google Scholar
• Martin S, Trevor-Jones E, Khan S, Shaw K, Marchment D, Kulka A, et al. The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 8:569–75.
   Google Scholar
• Oliveira De Almeida FE, Kelly A, Santana C, Oliveira De Carvalho F. Multidisciplinary care in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2021;42(3):911–23.
   Google Scholar
• Ng L, Khan F, Mathers S,. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syste Rev. 2009;(4):CD007425.
   Google Scholar
• Van Den Berg JP, Kalmijn S, Lindeman E, Veldink JH, De Visser M, Van Der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. 2005.
   Google Scholar